Abstract
Allergic dermatosis is a class of immunologic skin diseases manifested as intense itching, which potentially leads to a cycle of skin pain, damage, and infection. Information collected from clinical samples on health-related quality of life shows that some individuals may suffer from poorquality sleep, physical and emotional distress, and limitations in social functioning. Although many individual factors may moderate the impact of disease on quality of life, disease severity is consistently linked to amount of limitation. There are only sparse data from population surveys in which participants are not selected based on willingness to join a treatment trial for relief of symptoms. This article presents quality-of-life and disease burden data on 559 persons in a community survey who reported signs and symptoms consistent with allergic dermatosis. Quality of life was assessed using the Dermatology-specific Quality of Life (DSQL) questionnaire. Overall, greater disease severity was associated with higher DSQL scores. Noticeable deficits were reported among those who rated their disease as moderate or severe, especially in terms of physical discomfort, sleep disturbance, and negative self-perceptions and emotions. These complaints correlated significantly with out-of-pocket expenses for lotions and emollients to control skin disease. Despite these complaints, the median number of days from the last primary healthcare visit was 453 days, indicating that many dermatosis sufferers are not accessing expert medical care that could alleviate distress.
Similar content being viewed by others
References and Recommended Reading
World Health Organization: Constitution of the World Health Organization. Geneva: World Health Organization; 1947.
Berzon R, Hays RD, Shumaker SA: International use, application and performance of health-related quality of life instruments. Qual Life Res 1993, 2:367–368.
Larsen FS: Epidemiology and socioeconomic impact of allergic skin diseases. In Allergic Skin Disease: A Multidisciplinary Approach. Edited by Leung DM, Greaves MW. New York: Marcel Dekker; 2000:1–20.
Finlay AY: The Dermatology Life Quality Index: initial experience with a practical measure. In Care Management of Skin Diseases: Life Quality and Economic Impact. Edited by Rajagopalan R, Sherertz E, Anderson RT. New York: Marcel Dekker; 1998.
Rajagopalan R, Sherertz E, Anderson RT: Care Management of Skin Diseases: Life Quality and Economic Impact. New York: Marcel Dekker; 1998. This edited volume, written for clinicians and researchers, describes the HRQL impact of skin disease.
O’Donnell BF, Lawlor F, Simpson J, et al.: The impact of chronic urticaria on the quality of life. Br J Dermatol 1997, 136:197–201.
Berth-Jones J, Finlay AY, Zaki I, et al.: Cyclosporin in severe childhood dermatitis: a multicenter study. J Am Acad Dermatol 1996, 34:1016–1021.
Salek MS, Finlay AY, Luscombe DK, et al.: Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 1993, 129:422–430.
Finlay AY: Measurement of disease activity and outcome in atopic dermatitis. Br J Dermatol 1996, 135:509–515.
Shuster S, Fisher GH, Harris E, Binnell D: The effect of skin disease on self image. Br J Dermatol 1978, 99(suppl 16):18–19.
Linnet J, Jemec GB: An assessment of anxiety and dermatology life quality in patients with atopic dermatitis. Br J Dermatol 1999, 140:268–272.
Eun HC, Finlay AY: Measurement of atopic dermatitis disability. Ann Dermatol 1990, 2:9–12.
Czech W, Brautigam M, Weidinger G, Schopf E: A body-weightindependent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. J Am Acad Dermatol 2000, 42:653–659.
Greaves MW: Chronic urticaria. N Engl J Med 1995, 332:1767–1772.
Hunt S, McKenna SP, Williams J: Reliability of a population survey tool for measuring perceived health problems: a study of patients with osteoarthritis. J Epidemiol Community Health 1981, 35:297–300.
Poon E, Seed PT, Greaves MW, Kobza-Black A: The extent and nature of disability in different urticarial conditions. Br J Dermatol 1999, 140:667–671. This is one of the few published reports on HRQL with urticaria.
Holness DL: Results of a quality of life questionnaire in a patch test clinic population. Contact Dermatitis 2001, 44:80–84.
Anderson RT, Rajagopalan R: Development and validation of a quality of life instrument for cutaneous diseases. J Am Acad Dermatol 1997, 37:41–50.
Rajagopalan R, Anderson RT: The profile of a patient with contact dermatitis and a suspicion of contact allergy (history, physical characteristics, and dermatology-specific quality of life). Am J Contact Dermatitis 1997, 8:26–31.
Rajagopalan R, Anderson RT, Sarma S, et al.: The use of decision-analytical modelling in economic evaluation of patch testing in allergic contact dermatitis. Pharmacoeconomics 1998, 14:79–95.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Anderson, R.T., Rajagopalan, R. Effects of allergic dermatosis on health-related quality of life. Curr Allergy Asthma Rep 1, 309–315 (2001). https://doi.org/10.1007/s11882-001-0041-3
Issue Date:
DOI: https://doi.org/10.1007/s11882-001-0041-3